id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-0575-0045,FDA,FDA-2013-D-0575,Guidance for Industry; Expedited Programs for Serious Conditions – Drugs and Biologics - Final Guidance,Other,Guidance,2023-12-01T05:00:00Z,2023,12,2023-12-01T05:00:00Z,,2026-01-03T12:40:21Z,,1,0,09000064862bd2eb